Literature DB >> 7888232

Comparison of the sensitivities of primary isolates of HIV type 2 and HIV type 1 to antiviral drugs and drug combinations.

S W Cox1, K Apéria, J Albert, B Wahren.   

Abstract

The sensitivity of primary isolates of HIV-2 to the antiretroviral drugs 3'-azido-3'-deoxythymidine (AZT), 2',3'-dideoxyinosine (ddI), and 3'-fluoro-3'-deoxythymidine (FLT) was measured in vitro in PBMCs and compared to that of primary isolates of HIV-1. HIV-2 isolates showed a similar sensitivity to the drugs compared to HIV-1 isolates. Both the relative and the absolute potencies of the three drugs were similar for inhibition of HIV-1 or HIV-2 replication. The effect of combinations of the antiviral drugs was also studied. The combinations of AZT plus FLT, AZT plus ddI, and FLT plus ddI showed synergistic inhibition of three primary HIV-2 isolates, similar to that previously shown for primary HIV-1 isolates. These results indicate that primary isolates of HIV-2 from untreated persons show a level of sensitivity to antiviral nucleoside analogs similar to that shown by HIV-1 isolates, and are also synergistically inhibited by drug combinations shown to be synergistic against HIV-1. Therapeutic regimes with nucleoside analogs used clinically against HIV-1 infection may therefore also be similarly useful against infection with HIV-2.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7888232     DOI: 10.1089/aid.1994.10.1725

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  9 in total

1.  Emergence of drug resistance mutations in human immunodeficiency virus type 2-infected subjects undergoing antiretroviral therapy.

Authors:  B Rodés; A Holguín; V Soriano; M Dourana; K Mansinho; F Antunes; J González-Lahoz
Journal:  J Clin Microbiol       Date:  2000-04       Impact factor: 5.948

Review 2.  Antiretroviral drug resistance in human immunodeficiency virus type 2.

Authors:  Michel L Ntemgwa; Thomas d'Aquin Toni; Bluma G Brenner; Ricardo J Camacho; Mark A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2009-05-26       Impact factor: 5.191

3.  Synergistic inhibition of human immunodeficiency virus isolates (including 3'-azido-3'-deoxythymidine-resistant isolates) by foscarnet in combination with 2',3'-dideoxyinosine or 2',3'-dideoxycytidine.

Authors:  S Palmer; J Harmenberg; S Cox
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

4.  Sequence and drug susceptibility of subtype C reverse transcriptase from human immunodeficiency virus type 1 seroconverters in Zimbabwe.

Authors:  R W Shafer; J A Eisen; T C Merigan; D A Katzenstein
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

5.  The Nucleoside Analog BMS-986001 Shows Greater In Vitro Activity against HIV-2 than against HIV-1.

Authors:  Robert A Smith; Dana N Raugi; Vincent H Wu; Sally S Leong; Kate M Parker; Mariah K Oakes; Papa Salif Sow; Selly Ba; Moussa Seydi; Geoffrey S Gottlieb
Journal:  Antimicrob Agents Chemother       Date:  2015-09-21       Impact factor: 5.191

6.  Human immunodeficiency virus types 1 and 2 exhibit comparable sensitivities to Zidovudine and other nucleoside analog inhibitors in vitro.

Authors:  Robert A Smith; Geoffrey S Gottlieb; Donovan J Anderson; Crystal L Pyrak; Bradley D Preston
Journal:  Antimicrob Agents Chemother       Date:  2007-10-29       Impact factor: 5.191

7.  Quality of life of people living with HIV and AIDS and antiretroviral therapy.

Authors:  Oluwafemi O Oguntibeju
Journal:  HIV AIDS (Auckl)       Date:  2012-08-06

Review 8.  Managing resistance to anti-HIV drugs: an important consideration for effective disease management.

Authors:  A M Vandamme; K Van Laethem; E De Clercq
Journal:  Drugs       Date:  1999-03       Impact factor: 11.431

9.  SAMHD1 enhances nucleoside-analogue efficacy against HIV-1 in myeloid cells.

Authors:  Paula Ordonez; Simone Kunzelmann; Harriet C T Groom; Melvyn W Yap; Simon Weising; Chris Meier; Kate N Bishop; Ian A Taylor; Jonathan P Stoye
Journal:  Sci Rep       Date:  2017-02-21       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.